Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Performance Score | Market Cap | Revenue | EBITDA | Earnings | EPS | Revenue Growth Y/Y | Revenue Growth 5Y | Earnings Growth Y/Y | Earnings Growth 5Y | Earnings Date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KRYS | KRYSTAL BIOTECH INC | $4.52B | $50.70M | $17.90M | $10.93M | $0.40 | N/A | N/A | N/A | N/A | 2024-05-17 | |
| TGTX | TG THERAPEUTICS INC | $2.45B | $233.66M | $25.89M | $12.67M | $0.09 | 8,290.02% | 333.86% | N/A | N/A | 2024-06-14 | |
| SRPT | SAREPTA THERAPEUTICS INC | $12.37B | $1.40B | $91.13M | $16.90M | $0.41 | 43.83% | 34.11% | N/A | N/A | 2024-06-06 | |
| GMAB | GENMAB A | $19.00B | $2.40B | N/A | $633.48M | $0.97 | 16.77% | 39.38% | -17.74% | 21.77% | 2024-05-02 | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $15.82B | $2.47B | $359.85M | $205.46M | $1.09 | 13.74% | 10.23% | 194.59% | N/A | 2024-05-21 | |
| RPRX | ROYALTY PHARMA PLC | $16.77B | $2.35B | $1.32B | $1.13B | $2.54 | 5.24% | 5.58% | 2,440.00% | N/A | 2024-06-21 | |
| VNDA | VANDA PHARMACEUTICALS INC | $274.45M | $192.64M | $9.35M | $2.51M | $0.04 | -24.27% | -0.05% | -63.64% | -39.66% | 2024-05-17 | |
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.72B | $617.51M | $237.47M | $137.70M | $2.35 | 30.92% | N/A | -26.33% | N/A | 2024-05-29 | |
| HALO | HALOZYME THERAPEUTICS INC | $4.98B | $829.25M | $451.95M | $281.59M | $2.13 | 25.62% | 40.43% | 43.92% | N/A | 2024-05-07 | |
| CORT | CORCEPT THERAPEUTICS INC | $2.49B | $523.53M | $122.89M | $117.19M | $1.15 | 26.51% | 15.17% | 30.68% | 11.75% | 2024-05-17 | |
| INCY | INCYTE CORP | $11.89B | $3.77B | $1.11B | $745.44M | $3.33 | 8.58% | 13.53% | 128.08% | 22.65% | 2024-06-12 | |
| EXEL | EXELIXIS INC | $6.39B | $1.85B | $312.76M | $205.05M | $0.64 | 10.98% | 16.63% | 33.33% | -21.67% | 2024-05-30 | |
| JAZZ | JAZZ PHARMACEUTICALS PLC | $6.88B | $3.83B | $1.22B | $414.83M | $6.55 | 4.78% | 15.19% | N/A | -2.54% | ||
| TECH | BIO-TECHNE CORP | $11.55B | $1.14B | $372.91M | $224.16M | $1.41 | 2.25% | 10.93% | -15.57% | 17.11% | ||
| PBYI | PUMA BIOTECHNOLOGY INC | $238.63M | $235.64M | $47.52M | $21.59M | $0.46 | 3.34% | -1.25% | N/A | N/A | 2024-06-18 | |
| BNTX | BIONTECH SE | $21.38B | $4.15B | $1.51B | $1.01B | $4.21 | -76.96% | 96.02% | -89.58% | N/A | 2024-05-17 | |
| AMLX | AMYLYX PHARMACEUTICALS INC | $130.82M | $380.79M | $55.39M | $49.27M | $0.73 | 1,612.94% | N/A | N/A | N/A | 2024-06-06 | |
| CPRX | CATALYST PHARMACEUTICALS INC | $1.79B | $398.20M | $127.65M | $71.41M | $0.67 | 85.90% | 280.39% | -16.25% | N/A | 2024-05-30 | |
| NVO | NOVO NORDISK A S | $582.74B | $33.81B | $16.66B | $12.18B | $2.72 | 34.95% | 14.94% | 56.54% | 17.71% | 2024-05-03 | |
| MDXG | MIMEDX GROUP INC | $1.08B | $334.51M | $50.76M | $74.16M | $0.52 | 19.20% | -0.41% | N/A | N/A | 2024-06-05 | |
| UTHR | UNITED THERAPEUTICS CORP | $11.32B | $2.50B | $1.49B | $1.05B | $22.36 | 26.09% | 9.30% | 40.98% | N/A | 2024-06-25 | |
| REGN | REGENERON PHARMACEUTICALS INC | $99.17B | $13.12B | $4.69B | $3.95B | $37.05 | 7.76% | 20.58% | -8.54% | 10.34% | 2024-06-14 | |
| VRTX | VERTEX PHARMACEUTICALS INC | $103.88B | $9.87B | $4.61B | $3.62B | $14.05 | 10.51% | 26.49% | 8.33% | 11.26% | 2024-05-15 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.